Up next

Future-Proofing the Pharma Customer & Supplier Relationship

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

Continuous adaption
Evolving US tariff/trade policy is but one of the many variables that bio/pharmaceutical companies and their suppliers are facing. Global supply chains are always subject to geopolitical uncertainties, fluctuating economic conditions, and changes in trade and government policies, but the pace of that change has accelerated. Add to that the base challenge of increased product and supply chain complexity in the industry, and the need for bio/pharma companies and their suppliers to adapt is ever more important for supply assurance.

Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer

An executive panel at the DCAT Week program, Future-Proofing the Pharma Customer–Supplier Relationship, will share lessons learned, best practices, and innovative ways on how they are collaborating to enhance supply-chain visibility and resilience, mitigate risk, and optimize supply planning now and for what may lie ahead.

Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb

Participating in the panel of are:  Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer; Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems; Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb; and Sara Henneman, Vice President and General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific. The panel will be moderated by Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney.

The program, Future-Proofing the Pharma Customer–Supplier Relationship, is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The program, Future-Proofing the Pharma Customer–Supplier Relationship, will be held on Tuesday March 24, 2026, 11:00 AM–12:00 PM. Further information, including how to register, may be found here. The program is exclusive to DCAT Member Companies.

Recent Feature Articles

CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

By
CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Capital expansions for small-molecule API manufacturing, including HPAPIs, biologics, and fill-finish topped the news.

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2026 Member Company News Roundup 

By
What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs.

DCAT Week in Review: A Snapshot View of DCAT’s Education Programs

By
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).